In the present study, the tumor cells were positive for CD3 and thus, according to the World Health Organization (WHO) classification of lymphoid neoplasms guidelines (8), the immunological subtype was diagnosed as T-IV (positive for surface CD3 and negative for CD1a, irrespective of other markers). This evidence concerns the gene CD1A and lymphoid neoplasm.